Lux Research suggests corporations will need to integrate open-source with traditional patents for biotech innovations

In Washington, Lux Research stated that with synthetic biology rapidly gaining momentum, and a landmark U.S. Supreme Court judgment striking down an age-old biological patenting system, biotechnology companies need to incorporate open-source into their innovation plans in order to succeed in the emerging landscape. In a press release, Lux went on to state that alternatives to patents, like open-source computer code, standard protocols like GSM and HTML, and modular software have transformed information technology and accelerated product innovation in the space. Similarly, open-source genetic codes, such as modular DNA sequences, could hasten to market better drugs, bio-based materials and useful organisms.

More on the story.